Drug Trial Radar · NCT00542386
A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
642
Actual
Start
Dec 2007
Primary completion
Nov 2009
Study completion Nov 2009
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Oct 11, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III multi-centre study in two periods: the first period is a phosphate binder and lipid lowering drugs washout for 8 weeks, the second period is a double-blind, randomised, parallel group, fixed dose, for 12 weeks.
Conditions
- Chronic Kidney Disease
- Dialysis
- Hyperphosphatemia
- Dyslipidemia
Interventions
MCI-196Drug
3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
PlaceboDrug
3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Change in Serum PhosphorusTime frame: 12 weeks
- The Change in LDL-cholesterolTime frame: 12 weeks
Locations
73 sites in 8 countries. Site status is shown where the registry gives one.
Site not named
Ajka, Hungary
Site not named
Baja, Hungary
Site not named
Budapest, Hungary
Site not named
Esztergom, Hungary
Site not named
Győr, Hungary
Site not named
Hatvan, Hungary
Site not named
Kisvárda, Hungary
Site not named
Lecco, Italy
Site not named
Modena, Italy
Site not named
Pavia, Italy
Site not named
Roma, Italy
Site not named
Alor Star, Malaysia
Site not named
Ipoh, Malaysia
Site not named
Kajang, Malaysia
Site not named
Klang, Malaysia
Site not named
Kota Kinabalu, Malaysia
Site not named
Kuala Terengganu, Malaysia
Site not named
Kuantan, Malaysia
Site not named
Kuching, Malaysia
Site not named
Malacca, Malaysia
Site not named
Seremban, Malaysia
Site not named
Taiping, Malaysia
Site not named
Skopje, North Macedonia
Site not named
Lodz, Poland
Site not named
Płock, Poland
Site not named
Poznan, Poland
Site not named
Rybnik, Poland
Site not named
Warsaw, Poland
Site not named
Wroclaw, Poland
Site not named
Zielona Góra, Poland
Site not named
Arkhangelsk, Russia
Site not named
Armavir, Russia
Site not named
Chelyabinsk, Russia
Site not named
Chita, Russia
Site not named
Irkutsk, Russia
Site not named
Ivanovo, Russia
Site not named
Kaluga, Russia
Site not named
Kemerovo, Russia
Site not named
Khabarovsk, Russia
Site not named
Krasnodar, Russia
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.